CST, 2222S, Anisomycin

Chemical Modulators for studying in the research area. Product Usage Information Anisomycin is supplied as a lyophilized powder. For a 25 mg/ml stock, reconstitute the 10 mg in 400 µl DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 5-50 µg/ml for 5-60 minutes. Soluble in DMSO or MeOH. Storage Store lyophilized at -20C. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 1 month and store at -20C. Aliquot to avoid multiple freeze/thaw cycles. Background Anisomycin, an antibiotic produced by and , was originally described to inhibit protein-protein synthesis at the translational level (1). More recently, it is has been well characterized to strongly activate the stress kinases SAPK/JNK and p38 MAPK, as well as p70/85 S6 kinase in mammalian cells, which results in the rapid induction of immediate-early (IE) genes, such as c-fos, fosB, c-jun, JunB, and JunD (1). Investigators have demonstrated that anisomycin acts as a potent signaling agonist, synergizing with growth factors and phorbol esters to superinduce these IE genes (1,2). Research studies have demonstrated that anisomycin induces apoptosis in many cancer cell lines (3-5). Alternate Names apoptosis; c-fos; c-jun; fosB; JunD; p38 MAPK; p70/85 S6 kinase; phorbol esters; phospho junB; SAPK/JNK